Calimmune Inc. is a clinical-stage biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. The company was founded in 2006 from technology developed in the labs of Nobel Laureate David Baltimore, Ph.D. (California Institute of Technology), Irvin Chen, Ph.D. (University of California, Los Angeles) and Inder M. Verma, Ph.D. (Salk Institute for Biological Studies). Calimmune's lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune is developing a full product pipeline of therapeutic candidates to address the unique needs of individuals at different stages of HIV infection and with various treatment histories. The company is headquartered in Tucson, Arizona with labs and branch offices in Pasadena, California and Sydney, Australia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/27/15 | $15,000,000 | Series B |
Alexandria Real Estate Equities RA Capital Translational Accelerator | undisclosed |
